Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

3D-printed Laponite/alginate hydrogel-based suppositories as innovative platforms for AT-MSC secretome delivery in IBD treatment.

Munoz-Perez E., Igartua M., Santos-Vizcaino E., Hernandez RM.

Animal Study on Chronic Inflammation, Immune Modulation, published in Int J Biol Macromol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Biol Macromol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40494478
DOI
10.1016/j.ijbiomac.2025.145104

Abstract (original English)

The secretome of Mesenchymal Stromal Cells (MSCs) has demonstrated effectiveness in the treatment of Inflammatory Bowel Disease (IBD), offering a safer and more predictable alternative to the direct administration of MSCs. While parenteral administration is common, rectal delivery of the secretome provides targeted treatment for localized conditions such as ulcerative colitis and proctitis. Alginate-Laponite 3D-printed suppositories (Alg-Lap 3DPS) have shown a remarkable versatility in their ability to encapsulate and deliver therapeutic agents during previous studies. These formulations are also adaptable in the release of molecules with different physicochemical properties, and a Bovine Serum Albumin (BSA) displacement strategy has been proposed in order to promote their disintegration and controlled release. As such, these 3DPS formulations represent highly versatile pharmaceutical forms, enabling the rectal delivery of diverse molecules with controlled release characteristics. In this study, we combined the therapeutic potential of Adipose tissue derived-MSCs-secretome (AT-S) with the versatility and efficacy of Alg-Lap 3DPS. Herein, we demonstrate that these formulations are well-suited for the encapsulation and release of AT-S, confirming their ability to release bioactive factors from AT-S such as Galectin-9 upon applying the displacement strategy. Moreover, we validate

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AlginatesSilicatesPrinting, Three-DimensionalMesenchymal Stem CellsHydrogelsInflammatory Bowel DiseasesHumansSuppositoriesSecretomeAnimals

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research